Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918991 | 0.88 | LMNA (0.64) | LMNAPOLBMEN1KMT2APKM | |
| SCHEMBL31433394 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2ATDP1MAPTSMN1; SMN2 | |
| SCHEMBL7192810 | 0.82 | POLB (0.63) | LMNAPOLBMEN1KMT2APKM | |
| SCHEMBL6993793 | 0.81 | TSHR (0.60) | KMT2APKMTDP1SMN1; SMN2RAB9A | |
| SCHEMBL29949183 | 0.80 | ALDH1A1 (0.56) | LMNAPOLBMEN1KMT2APKM | |
| SCHEMBL158878 | 0.79 | HDAC2 (0.64) | LMNAPOLBMEN1KMT2APKM | |
| SCHEMBL6999658 | 0.79 | MPO (0.58) | LMNAMEN1KMT2APKMMAPT | |
| SCHEMBL13572118 | 0.79 | ALDH1A1 (0.67) | LMNAPOLBMEN1KMT2ATDP1 | |
| SCHEMBL6876467 | 0.78 | LMNA (0.53) | LMNAPOLBMEN1KMT2APKM | |
| SCHEMBL3862551 | 0.78 | MASP2 (0.46) | LMNAPOLBMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | claimed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | claimed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | claimed |
| CN-115515642-A | anti-CD 56 antibody-drug conjugates and their use in therapy | 麦克萨夫内部肿瘤公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | disclosed |
| CN-114514041-A | anti-PTCRA antibody-drug conjugates and uses thereof | 瑞泽恩制药公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-113735967-A | Human IgG1 FC region variants and uses thereof | 根马布私人有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-105229026-B | Human IgG1 FC region variants and uses thereof | 根马布私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | JOSTENS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | MEP1A, MEP1B, CTSZ | LMNA 3592/4885POLB 4315/4885MEN1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.